IN2014CN03647A - - Google Patents

Info

Publication number
IN2014CN03647A
IN2014CN03647A IN3647CHN2014A IN2014CN03647A IN 2014CN03647 A IN2014CN03647 A IN 2014CN03647A IN 3647CHN2014 A IN3647CHN2014 A IN 3647CHN2014A IN 2014CN03647 A IN2014CN03647 A IN 2014CN03647A
Authority
IN
India
Prior art keywords
dysfunctions
psychotic
alpha
provides methods
subject suffering
Prior art date
Application number
Other languages
English (en)
Inventor
Dominik Feuerbach
Mancilla Baltazar Gomez
Yunsheng He
Donald Johns
Lopez Cristina Lopez
Kevin Hall Mcallister
Nicole Pezous
Lisa Sandford
Markus Weiss
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014CN03647A publication Critical patent/IN2014CN03647A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
IN3647CHN2014 2011-10-20 2012-10-18 IN2014CN03647A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549319P 2011-10-20 2011-10-20
PCT/IB2012/055692 WO2013057687A2 (en) 2011-10-20 2012-10-18 Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment

Publications (1)

Publication Number Publication Date
IN2014CN03647A true IN2014CN03647A (ru) 2015-10-09

Family

ID=47297333

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3647CHN2014 IN2014CN03647A (ru) 2011-10-20 2012-10-18

Country Status (14)

Country Link
EP (1) EP2768507B1 (ru)
JP (1) JP6162705B2 (ru)
KR (1) KR102043077B1 (ru)
CN (1) CN103930112B (ru)
AU (1) AU2012324458B2 (ru)
BR (1) BR112014007485B1 (ru)
CA (2) CA2852268C (ru)
EA (1) EA034964B1 (ru)
ES (1) ES2776996T3 (ru)
IN (1) IN2014CN03647A (ru)
JO (1) JO3766B1 (ru)
MX (1) MX2014004621A (ru)
TW (1) TWI635861B (ru)
WO (1) WO2013057687A2 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
EA035335B1 (ru) 2014-10-20 2020-05-28 Ойстер Поинт Фарма, Инк. Способы лечения офтальмологических расстройств с применением варениклина
JP7090551B2 (ja) 2016-04-07 2022-06-24 オイスター ポイント ファーマ インコーポレイテッド 眼状態の治療方法
WO2017201364A1 (en) * 2016-05-20 2017-11-23 Vanda Pharmaceuticals Inc. Method for improving or enhancing cognition
CN107188900B (zh) * 2017-05-27 2019-09-06 北京师范大学 α7烟碱型乙酰胆碱受体的配体化合物及其应用
WO2020188051A1 (en) 2019-03-19 2020-09-24 Cambridge Cognition Limited Method and uses of diagnosing and recommending treatment for a psychotic disorder

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US5075216A (en) 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
WO1994016101A2 (en) 1993-01-07 1994-07-21 Koester Hubert Dna sequencing by mass spectrometry
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US20010049586A1 (en) 2000-04-05 2001-12-06 Roses Allen David Iterative analysis of non-responding population in the design of pharmacogenetic studies
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10211416A1 (de) 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
WO2004029050A1 (en) 2002-09-25 2004-04-08 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
WO2006065233A1 (en) 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
EP2431368B1 (en) 2006-05-19 2014-08-27 AbbVie Bahamas Ltd. CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009066107A1 (en) 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
CN102186826B (zh) 2008-10-13 2015-06-17 弗·哈夫曼-拉罗切有限公司 制备双环5-三氟甲氧基-1h-3-吲唑甲酰胺合成中的吲唑中间体的非重氮化方法
WO2010056622A1 (en) * 2008-11-11 2010-05-20 Targacept, Inc. TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS
TW201031664A (en) * 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
TWI558398B (zh) * 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α7活化劑之用途

Also Published As

Publication number Publication date
JP6162705B2 (ja) 2017-07-12
CA3083244C (en) 2023-01-03
ES2776996T3 (es) 2020-08-03
CA3083244A1 (en) 2013-04-25
EA201490832A1 (ru) 2015-12-30
EA034964B1 (ru) 2020-04-13
JP2015501306A (ja) 2015-01-15
TWI635861B (zh) 2018-09-21
KR102043077B1 (ko) 2019-11-11
CA2852268A1 (en) 2013-04-25
JO3766B1 (ar) 2021-01-31
TW201322980A (zh) 2013-06-16
CN103930112B (zh) 2018-11-09
CN103930112A (zh) 2014-07-16
CA2852268C (en) 2020-08-25
EP2768507B1 (en) 2019-12-11
BR112014007485A2 (pt) 2017-04-04
EP2768507A2 (en) 2014-08-27
WO2013057687A3 (en) 2013-07-11
AU2012324458B2 (en) 2016-05-19
WO2013057687A2 (en) 2013-04-25
MX2014004621A (es) 2014-08-22
KR20140081822A (ko) 2014-07-01
AU2012324458A1 (en) 2014-05-01
BR112014007485B1 (pt) 2022-05-31

Similar Documents

Publication Publication Date Title
IN2014CN03647A (ru)
JO3715B1 (ar) منشط مستقبل اسيتيل كولين الفا-7 النيكوتيني
PH12014500995A1 (en) Pak inhibitors for the treatment of cell proliferative disorders
HK1254745A1 (zh) Gpr119受體調節劑和對與其相關的障礙的治療
MX355543B (es) Macrociclos peptidomiméticos.
MX353143B (es) Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
HK1199030A1 (zh) 用於治療 受體相關疾病的取代的 -苯基吡啶
EP2817068A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEUROGENIC DISEASES OF THE POOL FLOOR
TW200745109A (en) Pyrrolo-pyridine kinase modulators
IN2014DN00288A (ru)
IN2014DN00286A (ru)
IN2014MN00093A (ru)
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
WO2008124849A3 (en) Pyrrolo-pyridine kinase modulators
SG10201603962TA (en) Anti-kir antibodies for the treatment of inflammatory disorders
GB201103062D0 (en) Method
IN2012DN02485A (ru)
IN2014MN01378A (ru)
MY162933A (en) Chemical compounds
MX2014004022A (es) Anticuerpos anti-htra1 y metodos de uso.
IL232334A0 (en) Modulators of the G protein-coupled mas receptor and the treatment of related disorders
WO2012173846A3 (en) Peptidomimetic macrocycles
EP2605655A4 (en) METHOD FOR TREATING EASY COGNITIVE IMPAIRMENT (MCI) AND RELATED DISEASES
EP3110974A4 (en) Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
SG10201804385YA (en) Stimulus responsive polymers for the purification of biomolecules